Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 3, 2003, Pages 145-152

  Lin, Chin Chung ^a   Yeh, Li Tain ^a   Vitarella, Domenico ^a   Hong, Zhi ^a  

^a Valeant Research and Development   (United States)

Author keywords

Liver targeting; Prodrug; Ribavirin; Safety; Viramidine

Indexed keywords

PRODRUG; RIBAMIDINE; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ERYTHROCYTE; HEMOLYTIC ANEMIA; HEPATITIS C; MALE; MONKEY; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; WHOLE BODY AUTORADIOGRAPHY;

EID: 0041736493     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400304     Document Type: Article

References (25)

1. Barnard D (2002). Viramidine (Ribapharm) Current Opinion in Investigational Drugs 3:1595-1599.
2. Canonico P-G, Kend M & Huggins J (1983) The toxicology and pharmacology of ribavirin in experimental animals. In R-A Smith, V Knight & J-AD. Smith (ed). Clincial Applications of Ribavirin. New York: Academic Press.
3. Canonico P-G, Kastello M-D, Spears C-T, Brown E-A & Jenkins D-E (1984) Effect of ribavirin on red blood cells. Toxicology & Appllied Pharmacology 74:155-162.
4. Connor E, Morrison S, Lane J, Oleske J, Sonke R-L & Connor J. (1993) Safety and tolerance and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infections. Antimicrobial Agents & Chemotherapy 37:532-539.
5. Davis G-L, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S-C, Trepo C, Shiffman M-L, Zeuzem S, Craxi A, Ling M-H & Albrecht J (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New England Journal of Medicine 339:1493-1499.
6. Ferrara E-A, Oishi J-S, Wannemacher R-W & Stephen E-L (1981) Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and Rhesus monkeys. Antimicrobial Agents & Chemotherapy 19:1042-1049.
7. Fried M-W, Shiffman M-L, Reddy K-R, Smith C, Marinos G, Goncales F-L Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347:975-982.
8. Hong Z & Cameron C-E. (2002) Pleiotropic mechanisms of ribavirin antiviral activities. Progress in Drug Research 59:41-69
9. 5)-nucleoside transporter. British Journal of Pharmacology 123:1587-1592.
10. Laskin, O-L, Longstreth J-A, Hart C-C, Scavuzzo D, Kalman C-M, Connor J-D & Robert R-B (1987) Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clinical Pharmacology & Therapeutics 41:546-555.
11. Lertora J-J, Rege A-B, Lacour J-T, Ferencz N, George W-J, VanDyke R-B, Agrawal K-C & Hyslop N-E (1991) Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clinical Pharmacology & Therpeutics 50:442-449.
12. 14C]ribavirin in rats and cynomolgus monkeys. Antimicrobial Agents & Chemotherapy, in press.
13. Lindsay K-L, Trepo C, Heintges T, Shiffman M-L, Gordon S-C, Hoefs J-C, Schiff E-R, Goodman Z-D, Laughlin M, Yao R & Albrecht J-K (2001). A randomized double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
14. Manns M-P, McHutchison J-G, Gordon S-C, Rustgi V-K, Shiffman M, Reindollar R, Goodman Z-D, Koury K, Ling M, Albrecht J-K & the International Hepatitis Interventional Therapy Group (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 358:958-965.
15. McHutchison J-G, Gordon S-C, Schiff E-R, Mitchell M-D, Shiffmann M-L, Lee W-M, Rustgi V-K, Goodman Z-D, Ling M-H, Cort S & Albrecht J-K (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339:1485-1492.
16. Page T & Connor J-D (1990) The metabolism of ribavirin in erythrocytes and nucleated cell. International Journal of Biochemistry 22:379-383.
17. Poynard T, Marcellin P, Lee S-S, Nieerau C, Minuk G, Ideo G & Bain V-H (1998) Randomized trial of Interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C Virus. Lancet 352:1426-1432.
18. Sidwell R-W, Huffman J-H, Khare L-B, Allen L-B, Witkowski J-T & Robins R-K (1972) Broad-spectrum antiviral activity of virazole:1-beta-D Ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
19. Sidwell R-W, Robin R-K & Hillyard I-W (1979) Ribavirin: an antiviral agent. Pharmacology & Therapeutics 6:123-144.
20. Sidwell R-W, Huffman J-H, Barnard D-L & Pifat D-Y (1998) Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. Antiviral Research 110:193-207.
21. Stephen E, Jones C-J, Peters C-J, Eddy G-A, Loizeaux P-S & Jahrling P-B (1980) Ribavirin treatment of Toga-, Aren-, and Bunyavirus infections in subhuman primates and other laboratory species. In RA Smith and W Kirkpatrick (ed). Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press.
22. Tam R-C, Pai B, Bard J, Lim C, Averett D-R, Phan U-T & Milovanovic T (1999) Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. Journal of Hepatology 30:376-382.
23. Tam R-C, Lau J-Y & Hong Z (2001) Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chemistry & Chemotherapy 12:261-272.
24. Waddell W-J, Ullberg S & Marlowe C (1969) Localization of the bicarbonate and carbonate pools by whole-body autoradiography. Archival International Physiology & Biochemistry 77:1-9.
25. Wu J-Z, Walker H, Lau J-Y & Hong Z (2003) Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrobial Agents & Chemotherapy 47:426-431.